Thursday, June 11, 2026
🇺🇸 FDA

pharma · Atherosclerosis · Non-small Cell Lung Cancer (NSCLC)

MSD Merck Sharp

Merck Sharp and Dohme

MSD Merck Sharp clinical programs — 217 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
WERFTESTRASSE 4, Lucerne, 6005, ch HQ
61 Employees
EMA registrant Type
Company details
Status
Public
HQ
WERFTESTRASSE 4, Lucerne, 6005, ch
Employees
61
Programs
217
Drugs
180
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

MSD Merck Sharp projects

217 ClinicalTrials.gov programs sponsored by MSD Merck Sharp.

MSD Merck Sharp has 217 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

217 programs

Clinical programs

Page 3 of 5

  1. MK-1084-014

    Merck Sharp and Dohme

    Neoplasm malignant with KRAS G12C mutation

    phase 2 small molecule active

    1 trial

  2. MK-1167-008

    Merck Sharp and Dohme

    Alzheimer’s disease dementia

    phase 2 small molecule active

    1 trial

  3. MK-1200-002

    Merck Sharp and Dohme

    Advanced solid tumor

    phase 2 small molecule active

    1 trial

  4. MK-2060, Placebo to MK-2060

    Merck Sharp and Dohme

    Prevention of arteriovenous graft thrombosis

    phase 2 small molecule active

    1 trial

  5. MK-2140-006

    Merck Sharp and Dohme

    Aggressive and Indolent B-cell Malignancies (mantle cell lymphoma; chronic lymphocytic leukemia; follicular lymphoma; Richter’s syndrome)

    phase 2 small molecule active

    1 trial

  6. MK-2140-011

    Merck Sharp and Dohme

    Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 2 small molecule active

    1 trial

  7. MK-2214-004

    Merck Sharp and Dohme

    Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  8. MK-2400-01A

    Merck Sharp and Dohme

    Metastatic castrate resistant prostate cancer - mCRPC

    phase 2 small molecule active

    1 trial

  9. MK-2870-027

    Merck Sharp and Dohme

    Intermediate-risk Non-muscle Invasive Bladder Cancer

    phase 2 other active

    1 trial

  10. MK-3120

    Merck Sharp and Dohme

    High-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors

    phase 2 small molecule active

    1 trial

  11. MK-3120

    Merck Sharp and Dohme

    Advanced/metastatic solid tumor disease

    phase 2 small molecule active

    1 trial

  12. MK-3475-01A

    Merck Sharp and Dohme

    non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  13. MK-3475-01B

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  14. MK-3475-01C

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  15. MK-3475-01E

    Merck Sharp and Dohme

    Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  16. MK-3475-01F

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  17. MK-3475-01H

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  18. MK-3475-01I

    Merck Sharp and Dohme

    Stage IV Squamous Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  19. MK-3475-01J

    Merck Sharp and Dohme

    Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC

    phase 2 small molecule active

    1 trial

  20. MK-3475-02A

    Merck Sharp and Dohme

    PD-1 refractory melanoma

    phase 2 small molecule active

    1 trial

  21. MK-3475-02B

    Merck Sharp and Dohme

    PD-1 refractory melanoma

    phase 2 small molecule active

    1 trial

  22. MK-3475-02C

    Merck Sharp and Dohme

    Stage IIIB or IIIC or IIID melanoma

    phase 2 small molecule active

    1 trial

  23. MK-3475-02D

    Merck Sharp and Dohme

    Advanced melanoma with brain metastases, PD-1 refractory or PD-1 naive

    phase 2 small molecule active

    1 trial

  24. MK-3475-03A

    Merck Sharp and Dohme

    Renal cell carcinoma

    phase 2 small molecule active

    1 trial

  25. MK-3475-03B

    Merck Sharp and Dohme

    Renal cell carcinoma

    phase 2 small molecule active

    1 trial

  26. MK-3475-03C

    Merck Sharp and Dohme

    Clear cell renal cell carcinoma

    phase 2 small molecule active

    1 trial

  27. MK-3475-04B

    Merck Sharp and Dohme

    Advanced Urothelial Carcinoma

    phase 2 other active

    1 trial

  28. MK-3475-04C

    Merck Sharp and Dohme

    Advanced Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  29. MK-3475-04D

    Merck Sharp and Dohme

    Urothelial carcinoma

    phase 2 small molecule active

    1 trial

  30. MK-3475-06B

    Merck Sharp and Dohme

    Advanced esophageal squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  31. MK-3475-06C

    Merck Sharp and Dohme

    Gastroesophageal cancer

    phase 2 small molecule active

    1 trial

  32. MK-3475-06D

    Merck Sharp and Dohme

    Gastroesophageal cancer

    phase 2 small molecule active

    1 trial

  33. MK-3475-06E

    Merck Sharp and Dohme

    Esophageal squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  34. MK-3475-365

    Merck Sharp and Dohme

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  35. MK-3475-495

    Merck Sharp and Dohme

    Stage IV non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  36. MK-3475-667

    Merck Sharp and Dohme

    Classical Hodgkin lymphoma in children and young adults

    phase 2 small molecule active

    1 trial

  37. MK-3475-B98

    Merck Sharp and Dohme

    Participants with extensive-stage small cell lung cancer

    phase 2 small molecule active

    1 trial

  38. MK-3475-B99

    Merck Sharp and Dohme

    First-line treatment of participants with extensive-stage small cell lung cancer

    phase 2 small molecule active

    1 trial

  39. MK-3475A

    Merck Sharp and Dohme

    Relapsed or Refractory Classical Hodgkin’s Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)

    phase 2 small molecule active

    1 trial

  40. MK-3475A-F11

    Merck Sharp and Dohme

    Melanoma, Renal Cell Carcinoma, Non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  41. MK-4830-002

    Merck Sharp and Dohme

    Primary peritoneal cancer/Fallopian tube cancer

    phase 2 small molecule active

    1 trial

  42. MK-5592-127

    Merck Sharp and Dohme

    Fungal infection

    phase 2 small molecule active

    1 trial

  43. MK-5684-01A

    Merck Sharp and Dohme

    Metastatic castration resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  44. MK-6024-017

    Merck Sharp and Dohme

    Metabolic Dysfunction-Associated Steatohepatitis

    phase 2 small molecule active

    1 trial

  45. MK-6070-002

    Merck Sharp and Dohme

    Small cell lung cancer

    phase 2 small molecule active

    1 trial

  46. MK-7684A-005

    Merck Sharp and Dohme

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

  47. MK-7902-009

    Merck Sharp and Dohme

    Recurrent or metastatic squamous cell carcinoma of the head and neck

    phase 2 small molecule active

    1 trial

  48. MK-7902-013

    Merck Sharp and Dohme

    Between ages 2 and 21 and have High Grade Glioma (HGG), Rhabdomyosarcoma (RMS), Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (pPNET), or other solid tumor types (except osteosarcoma)

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does MSD Merck Sharp have?

217 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.